141 related articles for article (PubMed ID: 34087785)
1. Risk of Cancer-Specific Death for Patients Diagnosed With Neuroendocrine Tumors: A Population-Based Analysis.
Hallet J; Law C; Singh S; Mahar A; Myrehaug S; Zuk V; Zhao H; Chan W; Assal A; Coburn N
J Natl Compr Canc Netw; 2021 Jun; 19(8):935-944. PubMed ID: 34087785
[TBL] [Abstract][Full Text] [Related]
2. All-Cause and Cancer-Specific Death of Older Adults Following Surgery for Cancer.
Chesney TR; Coburn N; Mahar AL; Davis LE; Zuk V; Zhao H; Hsu AT; Wright F; Haas B; Hallet J;
JAMA Surg; 2021 Jul; 156(7):e211425. PubMed ID: 33978695
[TBL] [Abstract][Full Text] [Related]
3. Competing Mortality in Patients With Neuroendocrine Tumors.
Low SK; Giannis D; Bahaie NS; Trong BLH; Moris D; Huy NT
Am J Clin Oncol; 2019 Aug; 42(8):668-674. PubMed ID: 31343423
[TBL] [Abstract][Full Text] [Related]
4. Metachronous and Synchronous Cancers in Patients with Neuroendocrine Tumors.
Verrico M; Rossi L; Tomao S; Colonna M; Vici P; Tomao F
Oncology; 2020; 98(1):10-15. PubMed ID: 31505502
[TBL] [Abstract][Full Text] [Related]
5. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.
Hallet J; Law CH; Cukier M; Saskin R; Liu N; Singh S
Cancer; 2015 Feb; 121(4):589-97. PubMed ID: 25312765
[TBL] [Abstract][Full Text] [Related]
6. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
7. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study.
Cai W; Tan Y; Ge W; Ding K; Hu H
Cancer Med; 2018 Jun; 7(6):2699-2709. PubMed ID: 29733523
[TBL] [Abstract][Full Text] [Related]
8. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes.
Hallet J; Davis LE; Mahar AL; Law CHL; Isenberg-Grzeda E; Bubis LD; Singh S; Myrehaug S; Zhao H; Beyfuss K; Moody L; Coburn NG
Oncologist; 2019 Oct; 24(10):1384-1394. PubMed ID: 31270268
[TBL] [Abstract][Full Text] [Related]
10. Second cancers in patients with neuroendocrine tumors.
Tsai HJ; Wu CC; Tsai CR; Lin SF; Chen LT; Chang JS
PLoS One; 2013; 8(12):e86414. PubMed ID: 24392036
[TBL] [Abstract][Full Text] [Related]
11. Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia.
Wyld D; Wan MH; Moore J; Dunn N; Youl P
Cancer Epidemiol; 2019 Dec; 63():101598. PubMed ID: 31539715
[TBL] [Abstract][Full Text] [Related]
12. Second primary cancers and survival among neuroendocrine tumor patients.
Bateni SB; Coburn NG; Law C; Singh S; Myrehaug S; Assal A; Hallet J
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37184947
[TBL] [Abstract][Full Text] [Related]
13. The epidemiology of metastases in neuroendocrine tumors.
Riihimäki M; Hemminki A; Sundquist K; Sundquist J; Hemminki K
Int J Cancer; 2016 Dec; 139(12):2679-2686. PubMed ID: 27553864
[TBL] [Abstract][Full Text] [Related]
14. Recurrence pattern and surveillance strategy for rectal neuroendocrine tumors after endoscopic resection.
Chung HG; Goh MJ; Kim ER; Hong SN; Kim TJ; Chang DK; Kim YH
J Gastroenterol Hepatol; 2021 Apr; 36(4):968-973. PubMed ID: 32864790
[TBL] [Abstract][Full Text] [Related]
15. Short-term mortality risks among patients with non-metastatic bladder cancer.
Zhai M; Tang C; Li M; Chen X; Jin Y; Ying X; Tang Z; Wang X; Wu Y; Sun C; Chen K; Guo X
BMC Cancer; 2020 Nov; 20(1):1148. PubMed ID: 33238972
[TBL] [Abstract][Full Text] [Related]
16. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
[TBL] [Abstract][Full Text] [Related]
17. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors.
Scott AT; Pelletier D; Maxwell JE; Sherman SK; Keck KJ; Li G; Dillon JS; O'Dorisio TM; Bellizzi AM; Howe JR
Ann Surg Oncol; 2019 Aug; 26(8):2525-2532. PubMed ID: 31011904
[TBL] [Abstract][Full Text] [Related]
18. Causes of Death After Neuroendocrine Tumors Diagnosis: A US Population-Based Analysis.
Sonbol MB; Saad AM; Gonzalez-Velez M; Starr J; Halfdanarson TR
Pancreas; 2021 Jan; 50(1):47-53. PubMed ID: 33370022
[TBL] [Abstract][Full Text] [Related]
19. Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor.
Grillo F; Albertelli M; Brisigotti MP; Borra T; Boschetti M; Fiocca R; Ferone D; Mastracci L
Neuroendocrinology; 2016; 103(5):452-9. PubMed ID: 26337010
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular and other competing causes of death among patients with cancer from 2006 to 2015: An Australian population-based study.
Ye Y; Otahal P; Marwick TH; Wills KE; Neil AL; Venn AJ
Cancer; 2019 Feb; 125(3):442-452. PubMed ID: 30311655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
